

**Supplementary Table 1. Baseline characteristics of patients included in efficacy analysis of FVC according to the dose of pirfenidone**

Demographic characteristics	Standard dose (n = 32)	Non-standard dose (n = 82)	p value
Male sex	28 (87.5)	58 (70.7)	0.062
Age, yr	68.8 ± 8.5	72.3 ± 8.6	0.051
Body mass index, kg/m <sup>2</sup>	25.5 ± 3.1	24.1 ± 3.0	0.028
Body surface area, m <sup>2</sup>	1.79 ± 0.14	1.68 ± 0.15	0.001
Smoking history			0.409
Current smoker	2 (6.5)	12 (15.0)	
Former smoker	20 (64.5)	43 (53.8)	
Never smoker	9 (29.0)	25 (31.3)	
Comorbidity			
Diabetes	6 (18.8)	16 (19.5)	0.926
Hypertension	6 (18.8)	17 (20.7)	0.813
Coronary arterial disease	2 (6.3)	7 (8.5)	1.000
Chronic obstructive pulmonary disease	3 (9.4)	6 (7.3)	0.709
Surgical lung biopsy	3 (9.4)	15 (18.3)	0.241
Definite UIP pattern on CT	28 (87.5)	70 (85.4)	1.000
Diagnosis (≤ 1 yr) of IPF	16 (50.0)	34 (41.5)	0.409
Pulmonary function test			
%FVC <sub>predicted</sub>	71.5 ± 9.3	73.7 ± 11.7	0.342
FVC, L	2.60 ± 0.54	2.42 ± 0.59	0.134
%DL <sub>CO</sub> <sub>predicted</sub>	62.3 ± 20.2	62.5 ± 16.6	0.965
Use of supplemental oxygen	0	2 (2.4)	1.000
6-Minute walk distance, m	446.6 ± 67.8	404.8 ± 104.7	0.016
mMRC grade	0.9 ± 0.7	1.4 ± 0.7	0.003
GAP stage			0.330
GAP I	16 (51.6)	50 (61.7)	
GAP II	15 (48.4)	31 (38.3)	
GAP III	0	0	
Previous treatment			0.627
No	25 (80.6)	60 (73.2)	
Steroid only	4 (12.9)	17 (20.7)	
Steroid + immunosuppressant	1 (3.2)	4 (4.9)	
Immunosuppressant only	1 (3.2)	1 (1.2)	
Combined treatment with pirfenidone			0.544
No	21 (65.6)	60 (73.2)	
Steroid only	11 (34.4)	21 (25.6)	
Steroid + immunosuppressant	0	1 (1.2)	

Values are presented as number (%) or mean ± SD.

FVC, forced vital capacity; UIP, usual interstitial pneumonia; CT, computed tomography; IPF, idiopathic pulmonary fibrosis; DL<sub>CO</sub>, diffusing capacity of the lungs for carbon monoxide; mMRC, modified Medical Research Council; CAP, Gender-Age-Physiology.